Girentuximab (Anti-CA9 / Carbonic anhydrase 9) | Carbonic Anhydrase antibody

Girentuximab (Anti-CA9 / Carbonic anhydrase 9) is a chimeric monoclonal antibody that targets and binds to carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). MW:145.5 KD.

Purity & Quality Control

Batch: A257801 Purity: 99% Protein concentration: 7.98mg/ml Endotoxin Level: ＜1EU/mg

99

Choose Selective Carbonic Anhydrase Inhibitors

Biological Activity

Description	Girentuximab (Anti-CA9 / Carbonic anhydrase 9) is a chimeric monoclonal antibody that targets and binds to carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). MW:145.5 KD.

Product Details

CAS No.	916138-87-9
Molecular Weight	150 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field